Anchiano Therapeutics Ltd.

General Information

(Note:  (Public offering) “Our ordinary shares are listed on the Tel Aviv Stock Exchange Ltd., or the TASE, under the symbol “ANCN.” On January 28, 2019, the last reported sale price of our ordinary shares on the TASE was NIS 10.72, or $2.91 per ordinary share (based on the exchange rate reported by the Bank of Israel on that date, which was NIS 3.680 = $1.00). Based on the last reported sale price of our ordinary shares on the TASE on January 28, 2019, we have assumed an initial public offering price of  $14.55 per ADS. “

We are a clinical-stage biotechnology company committed to engineering a targeted gene therapy to improve the standard of care for early-stage bladder cancer. We have discovered and are developing a biologic agent, inodiftagene, that we believe can deliver a new treatment to patients who have options that are limited in effectiveness and problematic in toxicity.

Employees: 17
Founded: 2011
Contact Information
Address 1/3 High-Tech Village, Givat Ram, P.O. Box 39264 Jerusalem, 9139102 Israel
Phone Number +972 (2) 548-6555
Web Address
View Prospectus: Anchiano Therapeutics Ltd.
Financial Information
Market Cap $95.6mil
Revenues $0 mil (last 12 months)
Net Income $-13.4 mil (last 12 months)
IPO Profile
Symbol ANCN
Exchange NASDAQ
Shares (millions): 2.7
Price range $11.50 - $11.50
Est. $ Volume $30.5 mil
Manager / Joint Managers Oppenheimer
CO-Managers Ladenburg Thalmann/ LifeSci Capital
Expected To Trade:
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change